Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085956 | 0.70 | MAOA (0.33) | MAOALMNAPOLBSMN1; SMN2 | |
| SCHEMBL6727353 | 0.66 | MAOB (0.48) | ALOX15MAPK1MAOALMNAKMT2A | |
| SCHEMBL3042997 | 0.65 | MAOA (0.44) | MAOALMNAPOLBSMN1; SMN2 | |
| SCHEMBL3038929 | 0.59 | MAOA (0.54) | MAOA | |
| SCHEMBL5912909 | 0.55 | LMNA (0.78) | HSD17B10ALOX15MAPK1LMNAMEN1 | |
| SCHEMBL11570619 | 0.53 | PSMD14 (0.44) | ALOX15MAPK1LMNAMEN1KMT2A | |
| SCHEMBL9462764 | 0.52 | MAPT (0.63) | HSD17B10ALOX15MAPK1LMNAMEN1 | |
| SCHEMBL686422 | 0.51 | — | — | |
| SCHEMBL30270516 | 0.50 | LMNA (1.00) | HSD17B10ALOX15MAPK1LMNAMEN1 | |
| SCHEMBL2636675 | 0.50 | LMNA (1.00) | HSD17B10ALOX15MAPK1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | HSD17B10 1367/4885ALOX15 3786/4885MAPK1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.